BISCHOFBERGER NORBERT W 4

What Happened

• Norbert W. Bischofberger, a director of Vir Biotechnology (VIR), was granted a total of 24,000 equity awards on May 27, 2026: 8,000 restricted stock units (RSUs) and 16,000 derivative awards (stock option/derivative).
• Both awards were granted at $0.00 per share (i.e., a compensation grant rather than a market purchase) and are scheduled to vest in full on May 27, 2027. The filing notes the 16,000-share award is a derivative that will become exercisable when it vests.

Key Details

• Transaction date: 2026-05-27; Filing date (Form 4): 2026-05-28 (timely).
• Amounts and price: 8,000 RSUs @ $0.00; 16,000 derivative shares @ $0.00. Total granted = 24,000 shares.
• Vesting/exercise: RSUs and the derivative award will vest in full on May 27, 2027; the derivative will become exercisable then.
• Holding: The filing notes some shares are held in the name of Nextquest, LLC, of which Bischofberger is a managing member.
• Shares owned after transaction: Not specified in the Form 4.
• Transaction code: A = Award/Grant (no sale or purchase reported).

Context

• RSU grants and option awards are a common form of executive/director compensation and do not represent an open-market purchase or sale. They typically become valuable only after vesting and (for options) exercise.
• For retail investors, such grants signal company compensation activity but are not direct indicators of insider buying or selling intent.